Avatan-T sterile ophthalmic solution is used to decrease of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
Travoprost and Timolol reduce intraocular pressure (IOP) by complementary mechanisms of action. Travoprost is a prostaglandin analogue which reduces IOP by increasing trabecular outflow & uveoscleral outflow. Timolol is a non-selective beta adrenergic receptor blocker that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane stabilizing) activity. It lowers IOP by decreasing the formation of aqueous humor in the ciliary epithelium.
Use in adults : The dose is one drop of Travast Plus in the conjunctival sac of the affected eye(s) once daily, in the morning or evening. It should be administered at the same time each day. Paediatric patients : The efficacy and safety of Travast Plus in patients below the age of 18 years have not been established.
No serious ophthalmic or systemic undesirable effects related to Travast Plus were reported. The most frequently reported treatment-related undesirable effect was ocular hyperaemia. Other common side-effects may be keratitis, anterior chamber flare, eye pain, photophobia, eye swelling, conjunctival haemorrhage, corneal staining, ocular discomfort, visual acuity reduced, visual disturbance, blurred vision etc.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Contraindicated in patients who are hypersensitive to Travoprost, Timolol or any of the components of this preparation.
No specific interaction was observed with Travast Plus eye drops.
Like other topically applied ophthalmic agents, Travoprost and Timolol are absorbed systemically. Due to the beta-adrenergic component, timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta adrenergic blocking agents may occur.